http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 16:42:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Sharp+Shalini/26648059.html si-local-file:///var/storage/secattach/20260615/26648059.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Sharp+Shalini/26648059.html Mon, 15 Jun 2026 16:42:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Sharp+Shalini/26648059.html si-local-file:///var/storage/secattach/20260615/26648059.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Sharp+Shalini/26648059.html Mon, 15 Jun 2026 16:42:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Sequeira+Ramona/26648042.html si-local-file:///var/storage/secattach/20260615/26648042.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Sequeira+Ramona/26648042.html Mon, 15 Jun 2026 16:41:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Sequeira+Ramona/26648042.html si-local-file:///var/storage/secattach/20260615/26648042.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Sequeira+Ramona/26648042.html Mon, 15 Jun 2026 16:41:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Patton+Cynthia+M/26648024.html si-local-file:///var/storage/secattach/20260615/26648024.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Patton+Cynthia+M/26648024.html Mon, 15 Jun 2026 16:40:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Patton+Cynthia+M/26648024.html si-local-file:///var/storage/secattach/20260615/26648024.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Patton+Cynthia+M/26648024.html Mon, 15 Jun 2026 16:40:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Ozuah+Philip/26648011.html si-local-file:///var/storage/secattach/20260615/26648011.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Ozuah+Philip/26648011.html Mon, 15 Jun 2026 16:39:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Ozuah+Philip/26648011.html si-local-file:///var/storage/secattach/20260615/26648011.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Ozuah+Philip/26648011.html Mon, 15 Jun 2026 16:39:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Leone+Deborah+R/26647998.html si-local-file:///var/storage/secattach/20260615/26647998.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Leone+Deborah+R/26647998.html Mon, 15 Jun 2026 16:38:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Leone+Deborah+R/26647998.html si-local-file:///var/storage/secattach/20260615/26647998.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Leone+Deborah+R/26647998.html Mon, 15 Jun 2026 16:38:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+LAZARUS+ROCHELLE+B/26647986.html si-local-file:///var/storage/secattach/20260615/26647986.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+LAZARUS+ROCHELLE+B/26647986.html Mon, 15 Jun 2026 16:37:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+LAZARUS+ROCHELLE+B/26647986.html si-local-file:///var/storage/secattach/20260615/26647986.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+LAZARUS+ROCHELLE+B/26647986.html Mon, 15 Jun 2026 16:37:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Gayle+Helene+D/26647949.html si-local-file:///var/storage/secattach/20260615/26647949.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Gayle+Helene+D/26647949.html Mon, 15 Jun 2026 16:35:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Gayle+Helene+D/26647949.html si-local-file:///var/storage/secattach/20260615/26647949.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Gayle+Helene+D/26647949.html Mon, 15 Jun 2026 16:35:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Ezekowitz+Alan/26647931.html si-local-file:///var/storage/secattach/20260615/26647931.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Ezekowitz+Alan/26647931.html Mon, 15 Jun 2026 16:34:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Ezekowitz+Alan/26647931.html si-local-file:///var/storage/secattach/20260615/26647931.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+Ezekowitz+Alan/26647931.html Mon, 15 Jun 2026 16:34:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+ESSNER+ROBERT/26647917.html si-local-file:///var/storage/secattach/20260615/26647917.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+ESSNER+ROBERT/26647917.html Mon, 15 Jun 2026 16:32:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+ESSNER+ROBERT/26647917.html si-local-file:///var/storage/secattach/20260615/26647917.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Jun+12++Filed+by%3A+ESSNER+ROBERT/26647917.html Mon, 15 Jun 2026 16:32:00 -0400 O.50635033 OGN http://www.streetinsider.com/Corporate+News/Organon+gets+FDA+approval+for+expanded+TOFIDENCE+uses/26626571.html <p>Organon (NYSE: OGN) received U.S. Food and Drug Administration approval to expand the approved uses of TOFIDENCE (tocilizumab-bavi) injection to treat cytokine release syndrome and pediatric COVID-19 patients.</p><p>The FDA approved the supplemental Biologics License Application for TOFIDENCE, a biosimilar to ACTEMRA (tocilizumab), to include treatment of adults and pediatric patients 2 years and older with chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The approval also covers hospitalized adult and pediatric patients aged 2 years and older with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.</p><p>TOFIDENCE http://www.streetinsider.com/Corporate+News/Organon+gets+FDA+approval+for+expanded+TOFIDENCE+uses/26626571.html Wed, 10 Jun 2026 07:30:46 -0400 OGN http://www.streetinsider.com/FDA/Organon+gets+FDA+approval+for+expanded+TOFIDENCE+uses/26626571.html <p>Organon (NYSE: OGN) received U.S. Food and Drug Administration approval to expand the approved uses of TOFIDENCE (tocilizumab-bavi) injection to treat cytokine release syndrome and pediatric COVID-19 patients.</p><p>The FDA approved the supplemental Biologics License Application for TOFIDENCE, a biosimilar to ACTEMRA (tocilizumab), to include treatment of adults and pediatric patients 2 years and older with chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The approval also covers hospitalized adult and pediatric patients aged 2 years and older with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.</p><p>TOFIDENCE http://www.streetinsider.com/FDA/Organon+gets+FDA+approval+for+expanded+TOFIDENCE+uses/26626571.html Wed, 10 Jun 2026 07:30:46 -0400 OGN http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN